Tevogen announces clinical milestone in evolution of ExacTcell platform

Tevogen (TVGN) announced a clinical milestone in the evolution of its proprietary ExacTcell platform: completion of T cell target identification for an additional five human leukocyte antigen restrictions. This advancement significantly broadens the accessibility of Tevogen’s investigational precision T cell therapies by extending therapeutic reach beyond the single HLA-A 02:01 restriction used in the company’s initial proof-of-concept clinical trial, the results of which were published in Blood Advances. That study demonstrated the safety and feasibility of Tevogen’s third-party cytotoxic T lymphocyte therapy, TVGN 489, in high-risk patients with COVID-19. HLA type varies widely among individuals and population groups. HLA-A 02:01 was selected for the proof-of-concept trial because it is one of the most common HLA types in the United States, present in approximately 25% of the population. Collectively, the identification of five additional HLA targets will allow the manufacture of CTLs which would extend treatment to approximately 65% of the US population, bolstering coverage for minority populations with less common HLA types. The ExacTcell platform utilizes advanced immunological screening as well as laboratory testing to identify key targets recognized by the immune system across different HLA types. With this expanded coverage, Tevogen’s next generation of T cell therapies aims to reach a much wider range of patients affected by infectious diseases and cancers.